why choose us

300×250 Ad Slot

Research Article: Mediastinal lymph node dissection versus spared mediastinal lymph node dissection in stage IA non-small cell lung cancer presented as ground glass nodules: study protocol of a phase III, randomised, multicentre trial (MELDSIG) in China

Date Published: 2023-10-28

Abstract:
Introduction Radical surgery including mediastinal lymph node dissection is the standard treatment for early-stage non-small cell lung cancer (NSCLC). About 50% lung nodules are pure ground glass or part-solid nodules, which are predominantly clinical stage IA NSCLC. Non-solid nodules rarely develop mediastinal lymph node metastasis. Method and analysis A phase III study was started in China to evaluate the non-inferiority in overall survival of spared mediastinal lymph node dissection compared with mediastinal lymph node dissection in stage IA NSCLC. A total of 1362 patients will be enrolled from 4 institutions in 2–3 years. The second endpoints are relapse-free survival and perioperative data, including duration of hospitalisation, duration of chest tube placement, operation time, blood loss. Ethics and dissemination This protocol has been reviewed and approved by the Clinical Research Review Board of Tianjin Medical University Cancer Institute and Hospital. The findings will be disseminated in peer-reviewed publications. Trial registration number NCT04631770 .

Introduction:
Lung cancer is the leading cause of cancer-related death worldwide. 1 In patients who underwent radical surgery, about 50% were diagnosed as stage I disease. 2 Surgery including lobectomy and systematic lymph node dissection (LND) is the standard initial therapy even in early-stage non-small cell lung cancer (NSCLC). 3 Systematic LND could remove occult metastasis, thus provide accurate staging and improve survival. 4 However, radical LND also leads to more surgical trauma and prolonged operation time. An…

Read more

300×250 Ad Slot